PHILIP-MORRIS-INT
Philip Morris International Inc. (PMI) (NYSE: PM) has once again been recognized as a global leader in sustainability performance and disclosure by CDP—an international nonprofit that collects data to help decision-makers reduce risk, capitalize on opportunities and drive action toward a more sustainable world. In CDP’s most recent rankings, PMI earned a position on the prestigious Water Security A List, recognizing the company as a global leader in water security. PMI has also been placed on CDP’s Supplier Engagement Leaderboard, designating it as a global leader in engaging with its suppliers on climate change, and has achieved a ranking of A- for its Forest disclosure.
Last month, PMI also ranked—for the sixth year in a row—on CDP’s A List for climate change , recognizing PMI’s work to reduce its environmental impacts, end to end, in the midst of its historic transformation toward a smoke-free future. The company has been recognized for its actions and strategies to reduce emissions and manage climate risks in its supply chain in the past reporting year. PMI’s sustainable commitments have also been documented as part of the 50 Sustainability and Climate Leaders initiative.
“Being recognized by CDP for our sustainability efforts is both humbling and encouraging as we continue our transformation,” said Huub Savelkouls, PMI’s Chief Sustainability Officer. “Our work toward achieving a smoke-free future isn’t just about transforming our product, it’s also about completely transforming the value chain and keeping sustainability at the heart of everything we do. We intend to accelerate our efforts for even greater impact.”
PMI’s water strategy accounts for the risks it faces—including from natural disasters, water scarcity and agricultural supply chain instability—and drives action toward responsible use of water as a shared resource, taking into consideration the needs of local communities. As PMI increases its manufacturing capacity for smoke-free products—which requires more water than for cigarettes—the company is evolving its water strategy, with clean technology investments enabling water savings and water recycling. One example of this is PMI’s implementation of the Alliance for Water Stewardship (AWS) standard. In 2017, PMI became a member of AWS; just one year later, it certified its first manufacturing site, in Brazil, to the AWS standard. Five additional PMI factories were AWS certified in 2019, and the company is making good progress toward its goal of certifying all factories by 2025.
In addressing the A List companies, Paul Simpson, CEO of CDP, said: “Congratulations to the companies that achieved a position on CDP’s A List this year, for leading in environmental performance and transparency. The scale of the business risks from the climate emergency, deforestation and water insecurity are vast—as are the opportunities from addressing them—and it’s clear the private sector has a vital role to play at this critical time. The A List companies are leading the market in corporate sustainability, tackling environmental risks and setting themselves up to thrive in tomorrow’s economy.”
This year also marks the third consecutive year CDP has recognized PMI as a leader in supplier engagement. With more than 36,000 contracted suppliers, PMI’s total supply chain has a significant environmental, social and economic footprint that calls for comprehensive programs to address risks and achieve improvements. These programs have earned the company the distinction of being among the top 3 percent of organizations assessed by CDP, with PMI now included among the fewer than 160 companies on the Leaderboard.
With regard to combating deforestation, PMI has developed a zero deforestation manifesto and aims to have a net positive impact on forests associated with its tobacco supply chain by 2025. Additionally, as part of PMI’s Good Agricultural Practices , the company’s tobacco suppliers are expected to prevent biodiversity loss.
“Our commitment to a smoke-free future has enabled us to make significant strides in our transformation into a more sustainable company,” said Laurence Ruffieux, PMI’s Director of Operation Sustainability. “We’ve given great attention to the roles that water, forest and supplier engagement play within our value chain and are honored to be recognized by the CDP for our work here. The CDP recognition energizes us to further focus our efforts to mitigate climate change, and the scoring process will continue to inspire us and guide our progress.”
A global environmental impact nonprofit, CDP provides a framework of action through which companies can measure and manage environmental risks and opportunities, transparently report on progress and commit to corporate sustainability initiatives. The full methodology and criteria for the Climate Change, Water Security, and Forest evaluations are available here on CDP’s website.
Additional information about PMI’s sustainability actions and commitments are available in the company’s annual Sustainability Report and on PMI.com/Sustainability .
Philip Morris International: Delivering a Smoke-Free Future
Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, as well as smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the United States. In addition, PMI ships a version of its IQOS Platform 1 device and its consumables authorized by the U.S. Food and Drug Administration to Altria Group, Inc. for sale in the United States under license. PMI is building a future on a new category of smoke-free products that, while not risk-free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of Sept. 30, 2019, PMI estimates that approximately 8.8 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 51 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com .
About CDP
CDP is a global nonprofit that drives companies and governments to reduce their greenhouse gas emissions, safeguard water resources and protect forests. Voted number one climate research provider by investors and working with institutional investors with assets of US$96 trillion, we leverage investor and buyer power to motivate companies to disclose and manage their environmental impacts. Over 8,400 companies with over 50% of global market capitalization disclosed environmental data through CDP in 2019. This is in addition to the over 920 cities, states and regions who disclosed, making CDP’s platform one of the richest sources of information globally on how companies and governments are driving environmental change. CDP is a founding member of the We Mean Business Coalition. Visit https://cdp.net/en or follow us @CDP to find out more.
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20200204005438/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
